FIELD: biotechnology.
SUBSTANCE: group of inventions concerns antibodies with specificity for BTN2 and their application. An anti-BTN2 antibody with specificity for human butyrophylin-2A1 (BTN2A1) and human butyrophylin-2A2 (BTN2A2) is proposed. The antibody has at least one of the following functions: inhibits the production of IFN-γ and TNF-α by activated T-cells γ V9/Vδ2; inhibits the cytolytic function of activated T-cellsγ V9/Vδ2; inhibits proliferation of activated T-cellsγ V9/Vδ2. Also the following are proposed: a nucleic acid molecule that encodes the heavy chain and light chain of an anti-BTN2 antibody, a host cell containing the said nucleic acid, a pharmaceutical composition containing an anti-BTN2 antibody.
EFFECT: inventions may be applicable in the treatment of autoimmune diseases.
9 cl, 5 dwg, 3 tbl
| Title | Year | Author | Number |
|---|---|---|---|
| BTN2-SPECIFIC ANTIBODIES AND USE THEREOF | 2020 |
|
RU2821703C2 |
| ANTIBODIES TO BTN3A AND THEIR USE IN THE TREATMENT OF CANCER OR INFECTIOUS DISEASES | 2019 |
|
RU2800726C2 |
| CANCER-RELATED IMMUNOSUPPRESSION INHIBITOR | 2018 |
|
RU2805232C2 |
| ALLOSTERIC ANTIBODIES AGAINST HUMAN HER3 NON COMPETITIVE FOR NEUREGULIN AND USE THEREOF | 2013 |
|
RU2704228C2 |
| ANTIBODY OR FRAGMENT THEREOF WITH HIV-NEUTRALISING ACTIVITY | 2005 |
|
RU2380378C2 |
| USE OF THE ANTI-O-ACETYLATED GANGLIOSIDE GD2 ANTIBODY FOR IMPROVING THE THERAPEUTIC POTENTIAL OF DRUGS | 2017 |
|
RU2771173C2 |
| ANTIBODY OR FRAGMENT THEREOF, HAVING NEUTRALISING EFFECT ON HIV, BUT NOT ON IL2 | 2005 |
|
RU2393873C2 |
| HUMANIZED MONOCLONAL ANTIBODY SPECIFIC TO SYNDECAN-1 | 2015 |
|
RU2611685C2 |
| IMMUNOCYTOKINES BASED ON IL-15 AND IL-15Rα OF THE SUSHI DOMAIN | 2012 |
|
RU2763298C2 |
| ANTIBODIES TO CD38 AND COMBINATIONS WITH ANTIBODIES TO CD3 AND CD28 | 2018 |
|
RU2812910C2 |
